Pulse Biosciences, Inc., a company advancing its innovative nPulse technology that uses proprietary Nanosecond Pulsed Field Ablation energy, announced a research collaboration with The University of Texas MD Anderson Cancer Center to explore its nPulse Vybrance Percutaneous Electrode System for thyroid cancer treatment. The FDA has approved the Investigational Device Exemption for this first-in-human clinical feasibility study.
Health Technology Insights: Sculptra Earns MDR Certification and New Body Indication
MD Anderson researchers led by Victoria Banuchi, M.D., Associate Professor of Head & Neck Surgery, will conduct a clinical trial to evaluate the safety and effectiveness of nPulse technology in treating papillary thyroid microcarcinoma, a cancer affecting hundreds of thousands of patients in the United States. The trial is expected to begin in early 2026, will take place at two sites, and aims to enroll 30 subjects. Preclinical studies are also ongoing under a material transfer agreement to assess the effects of nsPFA energy on anaplastic thyroid carcinoma, one of the deadliest cancer types with a five-year survival rate below five percent.
Health Technology Insights: Nihon Kohden Showcases Advanced EEG Tech at AES 2025
Paul LaViolette, Co-Chairman and CEO of Pulse Biosciences, stated that the nonthermal mechanism of nsPFA energy, which minimizes scarring, fibrosis, and damage to surrounding tissues, makes nPulse technology a promising approach for treating both benign and malignant thyroid tumors. He expressed optimism that this collaboration will help determine the technology’s potential to improve patient outcomes.
The nPulse Vybrance Percutaneous Electrode System includes a percutaneous needle electrode designed to work with the nPulse Console. It delivers nsPFA energy with precision, allowing nonthermal removal of cellular tissue without harming noncellular structures or causing thermal necrosis. The system is FDA 510(k) cleared for soft tissue ablation in percutaneous and intraoperative procedures and is designed for non-cardiac applications.
Health Technology Insights: AstraZeneca Chooses Salesforce Agentforce for Global Engagement
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
